POLISCOPE
Back to feed
FEDERALhearing transcript

1971 Senate Hearing on the Drug Listing Act

Original title: Drug listing act, 1971: hearing before the Committee on Labor and Public Welfare, United States Senate, Ninety-second Congress, first session, on S. 2167, to amend the Federal Food, Drug, and Cosmetic Act to provide for a current listing of each drug manufactured, prepared, propagated, compunded, or processed by a registrant under that act, and for other purposes [and] H.R. 9936, to amend the Federal Food, Drug, and Cosmetic Act to provide for a current listing of each drug manufactured, prepared, propagated, compounded, or processed by a registrant under that act, and for other purposes, December 8, 1971.

July 20, 2026

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

The Frame

What this does

The hearing addressed the legislative framework for S. 2167 and H.R. 9936, which aimed to amend the Federal Food, Drug, and Cosmetic Act to ensure the FDA maintains an accurate, current list of all drug products in the marketplace.

Who is mentioned in the record

Potentially affected actors named in the source documents. Mention is not a position.

Drug manufacturers

Registrants under the Federal Food, Drug, and Cosmetic Act would be required to maintain and submit current listings of all drugs they manufacture or process.

Food and Drug Administration (FDA)

The agency would be responsible for managing the updated registry of drug products.

What changed

Last recorded activity July 20, 2026.

What's next

Next step not available in the current record.

Summary

This document is a transcript record of a 1971 Senate Committee on Labor and Public Welfare hearing regarding proposed legislation to require a comprehensive, updated registry of all drugs manufactured or processed by registered entities.

Key Facts

  • The hearing was held on December 8, 1971, by the Senate Committee on Labor and Public Welfare.
  • The session focused on two pieces of legislation: S. 2167 and H.R. 9936.
  • The proposed legislation seeks to amend the Federal Food, Drug, and Cosmetic Act.
  • The primary goal of the bills is to require a current, comprehensive listing of every drug manufactured, prepared, propagated, compounded, or processed by a registrant under the Act.

Frequently Asked Questions

What was the purpose of this hearing?
The hearing was held to discuss proposed legislation (S. 2167 and H.R. 9936) that would require drug manufacturers to provide the government with a current list of all drugs they produce.
What law was being amended?
The legislation proposed amendments to the Federal Food, Drug, and Cosmetic Act.

Why It Matters

The hearing addressed the legislative framework for S. 2167 and H.R. 9936, which aimed to amend the Federal Food, Drug, and Cosmetic Act to ensure the FDA maintains an accurate, current list of all drug products in the marketplace.

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Discoveries

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift90% confidence

Standardization of Drug Oversight

The hearing marks a transition toward centralized, mandatory reporting of all drug products to improve federal oversight of the pharmaceutical industry.

Connected Entities

otherFederal Food, Drug, and Cosmetic ActThe existing federal law being amended by the proposed legislation.Map →
organizationCommittee on Labor and Public WelfareThe Senate committee responsible for reviewing the proposed drug listing legislaMap →

Sources

Open source document

www.govinfo.gov

Analysis Score

0–100
  • Significance60
    How much this matters to a regular citizen
  • Controversy10
    Intensity of disagreement among stakeholders
  • Entertainment5
    Compellingness for a non-policy-wonk reader
  • Buzz5
    Current news / social attention level

Publisher tools

Share or embed this record

POLISCOPE publisher tools

Share or embed this record